B. Riley Securities Reiterates Buy on Climb Bio, Raises Price Target to $30

Benzinga Newsdesk www.benzinga.com Positive 80.1%

Neg 0% Neu 0% Pos 80.1%

B. Riley Securities analyst Mayank Mamtani reiterates Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $26 to $30.